Summit Therapeutics
SMMT
$17.40
-5.54%
Summit Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies, with a historical antibiotic candidate in ridinilazole for Clostridioides difficile infection and a lead oncology asset, ivonescimab, being developed in partnership with Akeso. The company has transformed its identity from a legacy anti-infectives story into a high-profile immuno-oncology player, positioning ivonescimab as a potential best-in-class PD-1/VEGF bispecific antibody that could challenge established checkpoint inhibitors. The current investor narrative is dominated by ivonescimab's clinical momentum, most recently highlighted by Akeso's Phase III win in biliary tract cancer where the drug outperformed AstraZeneca's Imfinzi, reinforcing the multi-cancer opportunity and driving sharp swings in SMMT shares. At the same time, the stock remains a battleground between bulls pricing in a multi-billion-dollar oncology franchise and skeptics focused on the absence of product revenue, widening losses, and the binary risk inherent in late-stage clinical development.…
SMMT
Summit Therapeutics
$17.40
Related headlines
Investment Opinion: Should I buy SMMT Today?
We assign a Hold rating on SMMT. The core thesis is that ivonescimab's clinical potential is promising, but the current valuation already prices in substantial success, and the binary risk of clinical failure is high. The analyst consensus is 'buy' with an average target of $29.18, implying 66.3% upside, but the wide target range ($10.99 to $41.68) and recent Jefferies downgrade to Hold highlight the divided sentiment.
Supporting evidence includes the recent Phase III win in biliary tract cancer, which validates the drug's efficacy and supports multi-billion-dollar revenue estimates. Analyst average revenue is projected at $3.83 billion, and estimated EPS averages $1.53, suggesting a path to profitability if approved. The balance sheet is strong with a current ratio of 9.87 and debt-to-equity of 0.032, and the company has successfully raised capital. However, the price-to-book of 26.74 is extremely high, and the company currently has no revenue and a quarterly burn of ~$100 million. The implied upside to the average target is significant, but the downside to the low target is -37.4%.
The biggest risks are clinical failure, financing dilution, and competitive pressure. The rating would upgrade to Buy if ivonescimab shows positive data in a major indication (e.g., non-small cell lung cancer) and the cash runway extends beyond 2027 without excessive dilution. It would downgrade to Sell if a pivotal trial fails or if the company announces a heavily dilutive financing at a discount. Relative to its history and peers, SMMT is overvalued on book value, but the valuation is justified only if the pipeline succeeds. Thus, we see the stock as fairly valued given the risk-reward balance, warranting a Hold.
Sign up to view all
SMMT 12-Month Price Forecast
SMMT presents a high-risk, high-reward opportunity centered on ivonescimab. The recent Phase III success and bullish analyst consensus support upside, but the valuation is stretched and the company is pre-revenue with a limited cash runway. The negative beta and wide target dispersion add to volatility. We would upgrade to bullish if ivonescimab shows positive data in a larger indication like lung cancer and the company secures financing without excessive dilution. We would downgrade to bearish if a pivotal trial fails or if the cash position deteriorates faster than expected.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Summit Therapeutics's 12-month outlook, with a consensus price target around $29.05 and implied upside of +66.9% versus the current price.
Average Target
$29.05
0 analysts
Implied Upside
+66.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$11 - $42
Analyst target range
Summit Therapeutics is covered by 13 analysts, with a consensus recommendation of "buy" and a recommendation mean of 1.76 (where 1 is strong buy and 5 is strong sell), indicating a bullish tilt. The average target price is $29.18, which implies roughly +66.3% upside from the current price of $17.55, a substantial gap that reflects significant optimism about ivonescimab's commercial potential. The consensus leans clearly bullish, supported by recent Buy ratings from HC Wainwright, Citizens, Guggenheim, Citigroup, and JMP Securities, though the sentiment is not unanimous. The target range is extremely wide, from a low of $10.99 to a high of $41.68, a spread of $30.69, or roughly 2.8x the low target, which signals very high uncertainty and low conviction in any single outcome. The high target of $41.68 assumes ivonescimab succeeds across multiple indications, drives billions in revenue (consistent with the $11.19 billion high revenue estimate), and captures significant share from established PD-1 therapies. The low target of $10.99 prices in clinical failure, competitive pressure, or severe dilution from future financing, and is below the current price, implying downside of about -37.4%. Institutional ratings show a mix of actions: Jefferies downgraded to Hold from Buy in March 2026, Barclays upgraded to Equal Weight from Underweight in December 2025, while HC Wainwright, Citizens, Guggenheim, Citigroup, and JMP maintained Buy or Outperform ratings. The wide target spread and the recent downgrade suggest the analyst community is divided on the binary risk, and the stock's negative beta of -1.243 further complicates the risk profile for portfolio construction.
Bulls vs Bears: SMMT Investment Factors
The bull case for SMMT rests on the clinical validation of ivonescimab, a potential best-in-class PD-1/VEGF bispecific, and a strong analyst consensus with 66% upside to the average target. The bear case centers on the absence of revenue, massive cash burn, and an extreme valuation that leaves no room for error. Currently, the bear evidence appears stronger on fundamental grounds: the company has no product revenue, losses are widening, and the price-to-book of 26.74 is stretched. However, the recent Phase III win and positive momentum have shifted sentiment, creating a battleground. The single most important tension is whether ivonescimab's clinical success will translate into commercial approval and adoption before the company exhausts its cash runway, making upcoming data readouts and financing decisions critical.
Bullish
- Ivonescimab Phase III win validates platform: Akeso's Phase III trial in biliary tract cancer showed ivonescimab outperformed AstraZeneca's Imfinzi, a major competitive validation. This de-risks the asset across multiple cancers and supports the multi-billion-dollar revenue estimates, with analyst average revenue projected at $3.83 billion.
- Analyst consensus bullish with 66% upside: 13 analysts rate SMMT a 'buy' with a mean recommendation of 1.76 and an average target price of $29.18, implying 66.3% upside from the current $17.55. Recent Buy ratings from HC Wainwright, Citizens, Guggenheim, Citigroup, and JMP reinforce the optimistic view.
- Strong balance sheet with low debt: The current ratio is 9.87 and debt-to-equity is just 0.032, indicating minimal leverage. Cash of $225.58 million provides a runway of roughly two to three quarters at the current burn rate, and the company has demonstrated access to capital markets, raising $429.18 million in Q4 2025.
- Short-term momentum accelerating: The stock is up 25.27% over three months and 16.23% over one month, significantly outperforming SPY by 22.23 and 17.29 percentage points, respectively. This relative strength suggests improving sentiment and potential for further mean-reversion upside.
Bearish
- No revenue and massive losses: SMMT reported $0 revenue in Q4 2025 and a net loss of $219.17 million, with trailing EPS of -$0.083. The company is pre-revenue and burning cash, with free cash flow of -$323.59 million on a trailing basis.
- Extreme valuation on book value: The price-to-book ratio is 26.74, far above typical clinical-stage biotech peers. This valuation prices in optimistic ivonescimab success, and any clinical setback could compress the multiple sharply toward the historical low of 4.96.
- Wide analyst target dispersion signals uncertainty: The analyst target range is $10.99 to $41.68, a spread of 2.8x the low target. This huge dispersion reflects low conviction and binary risk, with the low target implying 37.4% downside from the current price.
- Negative beta complicates portfolio fit: The beta of -1.243 is highly unusual, meaning the stock has historically moved inversely to the market. This makes it difficult to hedge and increases volatility, as evidenced by a max drawdown of -56.63%.
SMMT Technical Analysis
SMMT is in a volatile, range-bound recovery phase rather than a clean trend. Over the trailing year the stock is down 5.65%, but it has rebounded 25.27% over three months and 16.23% over the past month, with the current price of $17.55 sitting at roughly 31.9% of its 52-week range of $12.07 to $29.23. That positioning — closer to the low than the high — suggests the market is still repairing damage from a severe drawdown, with a max drawdown of -56.63% underscoring how punishing the prior decline was. Momentum has clearly improved in the short term, but the stock has not yet reclaimed the upper half of its range, so the recovery remains unconfirmed. Recent momentum is accelerating on a relative basis: the 1-month gain of 16.23% and 3-month gain of 25.27% contrast with the 1-year decline of 5.65%, a classic divergence where near-term strength is outpacing the longer-term trend. Relative strength versus SPY is strongly positive over 1 month (+17.29 percentage points) and 3 months (+22.23 points), even though it is negative over 1 year (-21.87 points), indicating the stock is in a sharp mean-reversion rally after a prolonged period of underperformance. The latest session added 3.24% on volume of about 4.28 million shares, and the short ratio of 7.72 suggests elevated short interest that could amplify upside moves if the rally continues, though it also signals persistent bearish conviction. Key technical levels are defined by the 52-week low at $12.07 as support and the 52-week high at $29.23 as resistance, with the current $17.55 price roughly $5.48 above support and $11.68 below resistance. A breakout above $29.23 would signal a full trend reversal and likely require fundamental validation from ivonescimab data, while a breakdown below $12.07 would confirm the longer-term downtrend and could trigger momentum-driven selling. The beta of -1.243 is highly unusual and implies the stock has historically moved inversely to the broader market, which complicates traditional hedging and position-sizing frameworks; combined with the wide 52-week range, this argues for smaller position sizes and wider stops.
Beta
-1.24
-1.24x market volatility
Max Drawdown
-56.0%
Largest decline past year
52-Week Range
$12-$29
Price range past year
Annual Return
-8.1%
Cumulative gain past year
| Period | SMMT Return | S&P 500 |
|---|---|---|
| 1m | +30.3% | -2.4% |
| 3m | +23.7% | +2.2% |
| 6m | +10.7% | +14.8% |
| 1y | -8.1% | +14.6% |
| ytd | -0.7% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SMMT Fundamental Analysis
Summit Therapeutics currently generates effectively no product revenue, with the most recent quarterly revenue reported at $0 and only a small $3.97 million license and service segment figure, reflecting its clinical-stage status. The company's income statement shows a Q4 2025 net loss of $219.17 million and EPS of -$0.29, while the trailing EPS is -$0.083, and the multi-quarter trend reveals a dramatic escalation in losses: net loss widened from -$62.91 million in Q1 2025 to -$565.71 million in Q2 2025 before moderating to -$231.79 million in Q3 and -$219.17 million in Q4. This loss trajectory is driven primarily by research and development spending, which surged from $51.27 million in Q1 2025 to $208.02 million in Q2 2025 and remained elevated at $147.29 million in Q4, alongside a massive $242.54 million stock-based compensation charge in Q4. The key fundamental question is whether this spending is building a commercial franchise or simply funding a cash burn with binary clinical risk. Profitability metrics are deeply negative: net margin is 0%, gross margin is 0%, ROE is -220.78%, and ROA is -101.61%, all consistent with a pre-revenue biotech investing heavily in clinical development. Gross profit is essentially nil (reported at -$4,355 in Q4 2025), and the company has no meaningful cost of revenue, so traditional margin analysis is not applicable; instead, investors should focus on the burn rate and the path to a potential commercial launch. The Q2 2025 spike in losses was largely accounting-driven, tied to stock-based compensation of $478.78 million, which is a non-cash item and therefore overstates the true cash burn. Balance sheet and cash flow metrics are the most reassuring part of the story: the current ratio is 9.87, debt-to-equity is just 0.032, and cash at the end of Q4 2025 was $225.58 million. However, free cash flow is deeply negative at -$323.59 million on a trailing basis, with Q4 2025 free cash flow of -$100.16 million and operating cash flow of -$99.99 million, meaning the company is burning roughly $100 million per quarter. The company has relied on external financing, issuing $429.18 million of common stock in Q4 2025 and $572.97 million net cash from financing, which funds the runway but dilutes shareholders; with a cash balance of $225.58 million against a ~$100 million quarterly burn, the runway is roughly two to three quarters without additional raises, making financing risk a central consideration.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-323587000.0B
Last 12 Months
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SMMT Overvalued?
Because Summit Therapeutics has negative net income (trailing EPS of -$0.083 and Q4 2025 net loss of $219.17 million), the PE ratio is not meaningful, and the reported trailing PE of -12.15 and forward PE of -14.65 are negative and therefore not usable for valuation. Similarly, the PS ratio is reported at 0 and the EV/EBITDA is -11.97, both distorted by the absence of revenue and negative EBITDA. The most relevant metric for this pre-revenue biotech is the price-to-book ratio of 26.74, which is extremely elevated and reflects the market capitalizing future ivonescimab cash flows rather than current book value; the forward PE of -14.65 versus trailing PE of -12.15 implies the market expects losses to narrow, consistent with analyst estimates of positive average EPS of $1.53 and average revenue of $3.83 billion. Peer comparison is challenging because Summit has no direct revenue or earnings, but its price-to-book of 26.74 is far above typical biotechnology sector levels, where many clinical-stage peers trade at single-digit to low-double-digit price-to-book multiples. The premium is justified only if ivonescimab becomes a multi-billion-dollar franchise; the analyst revenue estimate range of $584.7 million to $11.19 billion highlights the enormous dispersion in expectations. Against a sector where profitable large-cap biopharma trades at 15-20x earnings, Summit's negative earnings make it an outlier, and its valuation is effectively a call option on clinical and regulatory success. Historical context shows the stock's price-to-book has been extraordinarily volatile, ranging from 4.96 in Q1 2023 to 79.89 in Q3 2025, with the current 26.74 sitting in the middle of that wide band. The historical PE ratios have been negative throughout, so they provide no useful anchor, but the price-to-book trajectory shows the market has repeatedly repriced the equity as clinical news flow shifted. At 26.74x book, the stock is not cheap on any asset-based measure, meaning the market is pricing in optimistic expectations for ivonescimab; a clinical setback would likely compress this multiple sharply toward the lower end of its historical range.
PE
-12.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-12.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are severe for SMMT. The company generated $0 revenue in Q4 2025 and posted a net loss of $219.17 million, with trailing free cash flow of -$323.59 million. R&D spending remains elevated at $147.29 million in Q4, and the cash balance of $225.58 million against a ~$100 million quarterly burn implies a runway of only two to three quarters without additional financing. The debt-to-equity of 0.032 is low, but the company relies on equity raises, having issued $429.18 million in Q4 2025, which dilutes existing shareholders. The lack of product revenue and binary clinical risk mean that any negative trial outcome could rapidly deplete cash and force a distressed raise.
Market and competitive risks are equally daunting. SMMT trades at a price-to-book of 26.74, far above the biotechnology sector average, leaving it vulnerable to sharp multiple compression if ivonescimab data disappoints. The beta of -1.243 indicates the stock often moves inversely to the broader market, which can amplify volatility and complicate hedging. Competition in the PD-1/VEGF space is intense, with established players like AstraZeneca and Merck. Recent news of Akeso's Phase III win in biliary tract cancer is a positive, but it also raises the bar for future data. Additionally, the macro environment, with sticky inflation and geopolitical tensions, has recently triggered rotations out of rate-sensitive growth stocks, posing a sector risk.
In a worst-case scenario, ivonescimab fails a pivotal trial or faces regulatory rejection, leading to a collapse in analyst estimates and a sharp revaluation. The stock could fall to its 52-week low of $12.07, representing a 31.2% decline from the current price of $17.55. The analyst low target of $10.99 implies a 37.4% downside, and in a severe bear case, the stock could revisit its historical low price-to-book of 4.96, implying a much larger drawdown. Given the max drawdown of -56.63%, investors could lose over half their capital if the clinical narrative reverses.
FAQ
The key risks for SMMT include clinical failure, financing dilution, competitive pressure, and valuation compression. Clinical risk is paramount: ivonescimab is in late-stage trials, and any negative data could cause a sharp decline, as reflected in the analyst low target of $10.99. Financing risk is high with a quarterly cash burn of ~$100 million and only $225.58 million in cash, likely requiring a dilutive raise. Competitive risk comes from established PD-1/VEGF players like AstraZeneca and Merck. Valuation risk is significant given the 26.74 price-to-book, which leaves little room for error. Additionally, the negative beta of -1.243 means the stock may not hedge market downturns effectively.
Our 12-month forecast for SMMT includes a bull case (30% probability) with a target range of $35-$42, a base case (50% probability) of $25-$30, and a bear case (20% probability) of $11-$13. The base case is most likely, assuming ivonescimab continues to show promise but faces delays and the company raises capital at moderate dilution. The bull case hinges on positive Phase III data in a major indication and accelerated approval. The bear case would be triggered by clinical failure or a distressed financing. The analyst average target of $29.18 aligns with our base case, implying 66.3% upside from the current price.
SMMT is difficult to value using traditional metrics due to negative earnings and zero revenue. The price-to-book ratio of 26.74 is extremely high compared to typical clinical-stage biotech peers, which often trade at single-digit to low-double-digit multiples. This suggests the stock is overvalued on an asset basis, but the market is pricing in future cash flows from ivonescimab. The forward PE of -14.65 and PS ratio of 0 indicate no current earnings or sales to support the valuation. If ivonescimab succeeds, the stock could be undervalued relative to its potential; if it fails, the stock is significantly overvalued. Thus, the valuation is entirely dependent on clinical and regulatory outcomes.
SMMT is a high-risk, high-reward biotech stock that may be suitable only for investors with a high tolerance for volatility and a long-term horizon. The analyst consensus is 'buy' with an average target of $29.18, implying 66.3% upside, but the low target of $10.99 implies 37.4% downside. The company has no revenue and a cash runway of only 2-3 quarters, making financing risk a major concern. The recent Phase III win for ivonescimab is a positive, but the stock trades at a steep 26.74x book value. For those who believe in the clinical story, it could be a good buy on dips, but position sizing should be small given the binary risk.
SMMT is more suitable for long-term investment by risk-tolerant investors who can withstand volatility and have a multi-year horizon. The company is in a clinical-stage growth phase with no revenue, and the path to commercialization will take years. The negative beta of -1.243 and max drawdown of -56.63% indicate high volatility, making it less appropriate for short-term trading unless one is actively trading news events. A suggested minimum holding period is 3-5 years to allow for clinical readouts, regulatory approval, and market launch. However, investors should be prepared for significant price swings and potential dilution along the way.